Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

Published:2021-10 Issue:5 Volume:3 Page:100350
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

van Kleef Laurens A.^ORCID,Choi Hannah S.J.,Brouwer Willem P.,Hansen Bettina E.,Patel Keyur^ORCID,de Man Robert A.,Janssen Harry L.A.,de Knegt Robert J.,Sonneveld Milan J.^ORCID

Funder

Fujirebio Europe

Foundation for Liver and Gastrointestinal Research

Gilead Sciences

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference30 articles.

1. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study;Razavi-Shearer;Lancet Gastroenterol Hepatol,2018

2. Global Hepatitis Report 2017,2017

3. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians;Arends;Gut,2015

4. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

5. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis;Li;Lancet Gastroenterol Hepatol,2019

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier;Hepatology International;2024-08-06

2. Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study;Clinical Transplantation;2024-08

3. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients;Hepatology International;2024-07-16

4. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD;Scientific Reports;2024-06-11

5. Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level;Heliyon;2024-06